Niacin therapy shows no benefits, has some harmful effects

International study finds serious adverse effects among participants

2013-03-11

(Press-News.org) SAN FRANCISCO (March 9, 2013) — A highly anticipated study evaluating a combination of the vitamin niacin with the anti-flushing agent laropiprant finds the therapy provides no benefit to and may even be harmful for patients with vascular disease, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. Detailed trial data is presented here for the first time.

Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) is the largest-ever study of niacin, commonly used to raise high-density lipoprotein (HDL) or "good" cholesterol and lower low-density lipoprotein (LDL) or "bad" cholesterol. The four-year study tested a combination of extended-release (ER) niacin with laropiprant in patients at risk for cardiovascular problems such as heart disease and stroke. The 25,673 patients in the study were randomized to receive ER niacin/laropiprant 2g/40mg or a placebo, and all received commonly prescribed LDL cholesterol-lowering medication simvastatin (with or without ezetimibe). The study did not meet the primary endpoint of reducing the chances of a major vascular event, defined as the composite of non-fatal heart attack or heart-related death, stroke, or need for angioplasty or bypass surgery. Patients receiving ER niacin/laropiprant had a similar number of major vascular events as patients receiving placebo (13.2 vs. 13.7 percent, p=0.29).

The study also found unexpected and significant excesses of bleeding (2.5 vs. 1.9 percent) and infections (8.0 vs. 6.6 percent) among the ER niacin/laropiprant patients. In addition, significantly higher numbers of patients receiving the study drug suffered serious known side effects including new onset diabetes (9.1 vs. 7.3 percent), diabetic complications (11.1 vs. 7.5 percent), gastrointestinal problems such as indigestion and diarrhea (4.8 vs. 3.8 percent), and skin issues including itching and rashes (0.7 vs. 0.4 percent).

"We are disappointed that these results did not show benefits for our patients," said Jane Armitage, FFPH, FRCP, professor at the University of Oxford and the lead author of the HPS2-THRIVE study. "Still, finding out a drug is not helping people is just as important as finding that it has benefits—the net result is that people are healthier. Niacin has been used for many years in the belief that it would help patients and prevent heart attacks and stroke, but we now know that its adverse side effects outweigh the benefits when used with current treatments."

A high level of LDL cholesterol is a known risk factor for heart disease and stroke. Standard treatment for at-risk patients includes dietary and lifestyle changes, as well as commonly prescribed medications such as statins, cholesterol absorption inhibitors and resins. Still, heart disease and stroke continue to cause death and disability even in patients receiving these medications, notes Dr. Armitage, and there was hope that the addition of niacin to standard therapy would improve patient outcomes.

Niacin is a type of B-vitamin, but the therapeutic doses used to control cholesterol are about 100 times higher than the amount recommended as part of daily intake. Laropiprant was added to reduce the facial flushing caused by niacin. While there was some speculation that the trial's results may have been due to unexpected side effects of laropiprant, Dr. Armitage believes this is unlikely, as the lack of benefit on heart attacks and strokes is consistent with the recent AIM-HIGH study, which did not use laropiprant, and many of the side effects are known to be due to niacin.

In 2011, AIM-HIGH was halted early when researchers determined a lack of effect for niacin in reducing cardiovascular events. Some experts in the field dismissed AIM-HIGH's findings because of its smaller size and perceived lack of ability to demonstrate definitive outcomes. Dr. Armitage notes that the size and scope of HPS2-THRIVE make its findings about niacin's outcomes and side effects reliable.

Patients taking niacin preparations to prevent heart disease should consider talking with their health care providers to determine whether the therapy is appropriate to continue.

ER niacin/laropiprant has been approved in 70 countries and was being sold in 40. The Food and Drug Administration was awaiting results from HPS2-THRIVE to license the drug in the U.S. In response to preliminary findings, the drug manufacturer Merck announced in December 2012 that it no longer planned to take the drug before the FDA for approval and in January suspended ER niacin/laropiprant from markets worldwide.

###HPS2-THRIVE was funded by a grant to Oxford University from Merck & Co, which provided all of the study drugs. The study was designed, conducted and analyzed independently by the investigators at Oxford University. Dr. Armitage indicated no conflict of interest.

The ACC's Annual Scientific Session brings together cardiologists and cardiovascular specialists from around the world each year to share the newest discoveries in treatment and prevention. Follow @ACCMediaCenter and #ACC13 for the latest news from the meeting.

The American College of Cardiology is a nonprofit medical society comprised of 43,000 physicians, surgeons, nurses, physician assistants, pharmacists and practice managers. The College is dedicated to transforming cardiovascular care, improving heart health and advancing quality improvement, patient-centered care, payment innovation and professionalism. The ACC also leads the formulation of important cardiovascular health policy, standards and guidelines. It bestows credentials upon cardiovascular specialists, provides professional education, supports and disseminates cardiovascular research, and operates national registries to measure and promote quality care. For more information, visit cardiosource.org.

Dr. Armitage will be available to the media on Saturday, March 9, at 10:20 a.m. in Moscone Center, South, Room 300.

Dr. Armitage will present "HPS2-THRIVE: Randomized Comparison of Extended-Release (ER) niacin/laropiprant 2g Daily Versus Placebo in 25,673 Patients at High Risk Of Occlusive Vascular Events" on Saturday, March 9 at 9:40 a.m., in Moscone Center, South, Esplanade Ballroom.

Media Contacts Beth Casteel
240-328-4549
bcasteel@acc.org

Karen Addis
301-787-2394
acc@ecius.net

ACC.13 News Room
415-978-3511

ELSE PRESS RELEASES FROM THIS DATE:

Drug protects against kidney injury from imaging dye in ACS patients

2013-03-11

SAN FRANCISCO (March 10, 2013) —High doses of a popular cholesterol-lowering drug significantly reduced the rate of acute kidney injury caused by dye used in imaging in acute coronary syndrome patients who underwent a coronary procedure, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. This group of patients is at high risk for kidney damage related to contrast agents used in imaging tests. Previous studies have demonstrated the kidney-protective value of various statins administered before patients undergo ...

Encouraging early results for redesigned Sapien valve

2013-03-11

SAN FRANCISCO (March 10, 2013) — The new Sapien XT aortic valve showed a non-significantly lower rate of death and strokes at 30 days than the original model, and both valves demonstrated notably better short-term outcomes than seen with the Sapien system in PARTNER I, according to the first results from the PARTNER II study presented today at the American College of Cardiology's 62nd Annual Scientific Session. PARTNER II is the first randomized clinical trial involving the Sapien XT valve and the only one that compares the new device to the original FDA-approved Sapien ...

New biolimus stent equal to everolimus stent at 1 year

2013-03-11

SAN FRANCISCO (March 10, 2013) — In a match-up of Japan's top drug-releasing stent and a new device featuring a biodegradable coating, the newcomer delivered statistically comparable one-year results, according to data from the NEXT trial presented today at the American College of Cardiology's 62nd Annual Scientific Session. Drug-eluting stents are structures placed inside narrowed coronary arteries to restore proper blood flow. A polymer coating on these devices slowly releases a drug designed to prevent restenosis—another blockage at the same site—and prevent a second ...

Fewer adverse events with 'double kissing' crush stent than culotte

2013-03-11

SAN FRANCISCO (March 10, 2013) — Patients with a type of coronary lesion linked with poor prognosis fared significantly better with the stent technique known as double kissing crush than with culotte stenting, according to data from the DKCRUSH-III trial presented today at the American College of Cardiology's 62nd Annual Scientific Session. DKCRUSH-III is the first head-to-head comparison of double kissing (DK) crush and culotte stent techniques in coronary artery disease. The study focused on bifurcation lesions, which involve a main branch and a smaller side branch ...

Cangrelor superior to clopidogrel in CHAMPION PHOENIX trial

2013-03-11

SAN FRANCISCO (March 10, 2013) — The experimental anti-clotting drug cangrelor solidly outperformed commonly used clopidogrel in a large global trial of patients who underwent coronary stent procedures, according to data from the phase III CHAMPION PHOENIX study presented today at the American College of Cardiology's 62nd Annual Scientific Session. Cangrelor and clopidogrel interfere with the P2Y12 receptor, a platelet-surface protein that helps regulate blood clotting. Currently approved drugs in this class are effective in cutting down ischemic events—blood-flow reductions ...

New anti-clotting drug more effective than current treatment

2013-03-11

A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures. These data, from the phase III CHAMPION PHOENIX study, were presented at the American College of Cardiology's 62nd Annual Scientific Session and published simultaneously in the New England Journal of Medicine. Researchers report that the new drug, which is administered intravenously, reduced the odds of complications from stenting procedures. ...

Magnet ingestion by young children serious and growing problem

2013-03-11

Physicians and parents must be aware of the growing danger of magnet ingestion by children because magnets can adhere to each other and cause life-threatening problems such as bowel perforations, a new case study illustrates in CMAJ. "Modern magnet technology has transformed what was once an esoteric subtype of foreign-body ingestion into a common and lethal threat," writes Dr. Daniel Rosenfield, Department of Paediatrics, The Hospital for Sick Children (SickKids), with coauthors. In the past, magnet ingestion generally could be treated with a wait-and-see approach, ...

Therapies for ALL and AML targeting MER receptor hold promise of more effect with less side-effect

2013-03-11

Two University of Colorado Cancer Center studies show that the protein receptor Mer is overexpressed in many leukemias, and that inhibition of this Mer receptor results in the death of leukemia cells – without affecting surrounding, healthy cells. The first study, published today in the journal Oncogene, worked with acute myeloid leukemia (AML), for which current chemotherapies offer a cure rate of only about 55 percent. "In about 2/3 of all AML patients and about 90 percent of adult AML patients, we found that the Mer receptor was upregulated. Mer receptor protein ...

EARTH: Well-healed faults produce high-frequency earthquake waves

2013-03-11

Alexandria, VA – Much like our voices create sound waves with a variety of low and high pitches, or frequencies, earthquakes produce seismic waves over a broad spectrum. The seismic waves' frequencies determine, in part, how far they travel and how damaging they are to human-made structures. However, the inaccessibility of fault zones means that very little is known about why and how earthquakes produce different frequencies. With the help of a new tabletop model, scientists have now identified how a process known as fault healing can shape seismic waves and potentially ...

BGI Tech develops novel 'Ultra-Deep de novo' assembly solution for heterozygous genomes

2013-03-11

Shenzhen, China, March 11, 2013- BGI Tech Solutions Co., Ltd., also referred to as "BGI Tech", introduced today its novel assembly solution for facilitating heterozygous genomes research. This marks another technological breakthrough for BGI in heterozygous genome assembly after the completed genome sequencing of oyster, diamondback moth and pear. The availability of a reference genome for a species is the cornerstone for the in-depth understanding of its biological secrets and commercial values. However, a major obstacle that prevents scientists to easily crack the genome ...

LAST 30 PRESS RELEASES:

Early adoption of sodium-glucose cotransporter-2 inhibitor in patients hospitalized with heart failure with mildly reduced or preserved ejection fraction

New study finds atrial fibrillation common in newly diagnosed heart failure patients, and makes prognosis significantly worse

Quandela, the CNRS, Université Paris-Saclay and Université Paris Cité join forces to accelerate research and innovation in quantum photonics

Pulmonary vein isolation with optimized linear ablation vs pulmonary vein isolation alone for persistent AF

New study finds prognostic value of coronary calcium scores effective in predicting risk of heart attack and overall mortality in both women and men

Authoritative review makes connections between electron density topology, future of materials modeling and how we understand mechanisms of phenomena in familiar devices at the atomistic level